High-potent sterile manufacturing is one of the fastest-growing pharmaceutical sectors, driven by oncology biologics, antibody-drug conjugates (ADCs), peptides and other highly active compounds. While aseptic filling remains essential, manufacturers must simultaneously protect product sterility, operators and the surrounding environment. As occupational exposure limits decrease to the ng/m³ range, every reusable machine component leaving the filling isolator becomes a potential contamination source.
Containment therefore extends beyond the filling line and requires a manufacturing flow that integrates washing, decontamination, sterilization and controlled transfer as part of the overall Contamination Control Strategy.
We engineer the complete post-filling pathway for reusable components exposed to high-potent products. Instead of treating washing, decontamination and sterilization as independent operations, we design a validated manufacturing flow that safely returns contaminated components to production while protecting operators, classified areas and product quality.
Depending on the manufacturing strategy, reusable components can follow two validated pathways. The standard one combines automated washing with biological decontamination before sterilization.
Where operator safety, reduced classified footprint and simplified material flow are priorities, we integrate washing and steam sterilization in a single pass-through system, restoring the required cleanliness and sterility conditions while minimizing handling and intermediate transfers.
Independent pressure and temperature control applies counterpressure through heating and cooling, protecting 5–7 N seals while delivering effective terminal sterilization
Magazines leave the sterilizer and transfer directly toward secondary packaging, sustaining line continuity and eliminating manual product handling after treatment.
Robotic handling moves magazines from primary packaging to the sterilizer without product extraction or operator contact, maintaining throughput and a touchless production flow
Compatible reusable parts are packaged in bags or loaded into closed canisters before steam sterilization. The process is developed around the complete load configuration to govern air removal, steam penetration, condensate management and drying. Once treated, the selected packaging or transfer system preserves the sterile state during unloading, movement and introduction into the aseptic processing environment.
For reusable parts that cannot withstand steam, low-temperature H₂O₂ sterilization provides an alternative route when supported by material, geometry and packaging compatibility. The complete configuration is evaluated to establish sterilant access, microbial reduction, aeration and residual removal. The treated load then follows a protected transfer route designed to preserve its required state up to the aseptic interface.
Bulk stoppers are washed and steam sterilized in one integrated process developed to control cleanliness, sterility and residual moisture. Following treatment, the closures are discharged directly into a sterile transfer tank. This eliminates intermediate bagging and creates the starting point for a closed route from stopper preparation to automated delivery at the isolator.
When operator safety, simplified logistics and reduced classified footprint are priorities, washing and steam sterilization can be integrated into a single pass-through process. Cleaning and sterilization occur within one validated chamber, eliminating intermediate transfers while returning components directly in their required sterile state for aseptic production.
Where required by the manufacturing strategy, washed components undergo validated hydrogen peroxide decontamination before entering the clean preparation area. The process reduces biological contamination while avoiding thermal stress on sensitive assemblies and supporting a controlled transition between different manufacturing zones within the contamination-control strategy.
The automated manipulator connects treatment and point of use through controlled loading, unloading, movement and delivery operations. Depending on the selected route, it handles canisters, sterile tanks or treated materials and manages their interface with the isolator or filling line. Automation removes avoidable manual interventions precisely where exposure, repeated handling and open connections create the greatest vulnerability.
Reusable filling-line components are automatically cleaned to remove residues from highly potent products before subsequent processing. Washing parameters, chemistry, mechanical action and drying are developed around the component geometry and contamination profile, supporting cleaning validation while minimizing manual handling and operator exposure. The result is a repeatable process that prepares reusable components for the following contamination-control steps.
The rapid growth of biologics, nanoparticle-based medicines and Advanced Therapy Medicinal Products (ATMPs) is redefining the relationship between pharmaceutical formulations and primary packaging.
Interactions between proteins such as insulin, nanoparticles and container surfaces are well-recognised phenomena that can influence product stability, efficacy and patient safety. As these therapies become increasingly sensitive, material compatibility can no longer be considered an intrinsic property of the container alone.
When manufacturers seek to move away from EtO towards a method that reduces toxic-residue concerns and the potential burden on patients, workers and the environment, selecting an alternative sterilant is only the beginning.
This is particularly true for the low-temperature sterilization of RTU glass vials in their complete packaging configuration. The sterilant must pass through the outer transport box, multiple porous barriers and enclosed packaging interfaces before reaching the internal vial surfaces. The same structure must then release residual sterilant within an acceptable aeration time.
Because reusable filling-line parts may retain high-potent product residues after production. Once they leave the barrier system, they can become a contamination pathway for operators, adjacent rooms and subsequent manufacturing activities. The return flow must therefore be included in the facility Contamination Control Strategy.
The standard configuration uses an automated parts washer to remove product residues, followed by biological decontamination before the components enter the clean preparation area. Sterilization is then performed before the parts are returned to aseptic production.
It is particularly valuable when operator safety, reduced classified footprint and fewer transfers are priorities. Washing, rinsing and steam sterilization take place within one closed pressure vessel, eliminating the intermediate transfer between two separate machines and allowing clean-side unloading.
No. Washing removes product residues and supports cleaning validation, but it does not by itself establish sterility. Depending on the component, contamination risk and intended destination, the process may also require biological decontamination, steam sterilization or both.
Washing and biological decontamination address different risks. Washing removes chemical and product residues from component surfaces; decontamination reduces viable contamination before the load enters a cleaner area. The need for each phase must be defined by the contamination-control strategy and validated process flow.
It keeps washing and sterilization within a closed system and reduces manual transfers of contaminated or newly cleaned components. Fewer handling steps mean fewer opportunities for personnel exposure and less movement of potent residues through the facility.
It connects cleaning, decontamination, sterilization, classified-area boundaries and material transfer within one defined process. Instead of controlling only the filling isolator, the strategy also governs how exposed components are safely returned to production.
Not automatically. Suitability depends on component materials, geometry, load configuration, soil characteristics, steam compatibility and required cleaning and sterilization endpoints. The route must be developed and validated around the actual component family.
Knowledge Hub Regulatory
Read this article
